Reference | Patients | Histotype | Regimen | Response | Progression-free survival, months | Median overall survival, months | P |
---|---|---|---|---|---|---|---|
Reck et al. [3] | 658 | Adenocarcinoma | Docetaxel + nintedanib vs. docetaxel + placebo | 4.7% vs. 3.6% | 4.0 vs. 2.8 | 12.6 vs. 10.3 | 0.0359 |
Garon et al. [4] | 1253 | All histologies | Docetaxel + ramucirumab vs. docetaxel + placebo | 23% vs. 14% | 4.5 vs. 3.0 | 10.5 vs. 9.1 | 0.023 |
Brahmer et al [5] | 272 | Squamous | Nivolumab vs. docetaxel | 20% vs. 9% | 3.5 vs. 2.8 | 9.2 vs. 6.0 | <0.001 |
Borghaei et al. [6] | 582 | Adenocarcinoma | Nivolumab vs. docetaxel | 19% vs. 12% | 2.3 vs. 4.2 | 12.2 vs. 9.4 | 0.002 |
Herbst et al. [7] | 1034 | All histologies | Pembrolizumab 2 mg/kg vs. pembrolizumab 10 mg/kg vs. docetaxel | 18% vs. 18% vs. 9% | 3.9 vs. 4.0 vs. 4.0 | 10.4 vs. 12.7 vs. 8.5 | 0.0008 < 0.0001 |
Rittmeyer et al. [8] | 287 | All histologies | Atezolizumab vs. docetaxel | 14% vs. 13% | 2.8 vs. 4.0 | 13.8 vs. 9.6 | 0.0003 |
Soria et al. [9] | 795 | Squamous | Afatinib vs. erlotinib | 6% vs. 3% | 2.6 vs. 1.9 | 7.9 vs. 6.8 | 0.0077 |